Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 10/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | MARS1 | P56192 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238390 | 0.93 | MAPT (0.41) | LTC4SMAPTNR1H2NR1H3SMN1; SMN2 | |
| SCHEMBL239082 | 0.82 | LTC4S (0.62) | LTC4S | |
| SCHEMBL238838 | 0.79 | LTC4S (0.60) | LTC4S | |
| SCHEMBL239216 | 0.79 | LTC4S (0.62) | LTC4S | |
| SCHEMBL236679 | 0.78 | LTC4S (0.51) | LTC4SP4HTMNR1H2NR1H3 | |
| SCHEMBL27830986 | 0.77 | GCGR (0.52) | P4HTM | |
| SCHEMBL238391 | 0.77 | LTC4S (0.55) | LTC4S | |
| SCHEMBL2755502 | 0.70 | LTC4S (0.60) | LTC4S | |
| SCHEMBL236562 | 0.70 | LTC4S (0.49) | LTC4S | |
| SCHEMBL236386 | 0.70 | P4HTM (0.48) | LTC4SP4HTMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035217-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-02-09 | — | — | US | disclosed |
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035217-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | LTC4S 1/4885P4HTM 578/4885MAPT 3787/4885 |
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | LTC4S 1/4885P4HTM 403/4885MAPT 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.